Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.
about
A Blueprint for HIV Vaccine DiscoveryDevelopment of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infectionVirological features associated with the development of broadly neutralizing antibodies to HIV-1Controlling the HIV/AIDS epidemic: current status and global challengesEvolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.CRF01_AE-specific neutralizing activity observed in plasma derived from HIV-1-infected Thai patients residing in northern Thailand: comparison of neutralizing breadth and potency between plasma derived from rapid and slow progressors.HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencingBroadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection CohortSelection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.Cross-reactive broadly neutralizing antibodies: timing is everything.B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth.Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodiesMost rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoproteinDetection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds.Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulationsHIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.Natural infection as a blueprint for rational HIV vaccine design.Basic research in HIV vaccinology is hampered by reductionist thinking.An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response.Broadly neutralizing antibodies: An approach to control HIV-1 infection.Determinants of HIV-1 broadly neutralizing antibody induction.Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells.Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design.Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers.The Janus Face of Follicular T Helper Cells in Chronic Viral Infections.Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains.Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?Les anticorps anti-VIH-1 et la transmission virale de cellule à cellule
P2860
Q26829865-1626ACA5-11C6-4022-9DE8-C0CBE37A98FFQ27022652-8629DB63-E746-4F3F-8F64-D14AA253A1BCQ27025177-2BA70789-3A64-4CA2-9CC5-3B2E321E3B5EQ30420558-ABD403D3-DC71-47EC-BD86-B55C647022B1Q34478071-C4BA92F5-C589-4919-B387-3F21C587371FQ34545420-67F7621B-0CD2-41DC-9918-09E3B491FDF5Q34657046-E1B7613E-92C2-4712-8B84-5742248D2F31Q35894094-39165E38-0FC6-4787-8CC0-FD9B13C7F5A8Q35943521-DD640ED4-48B5-4FBD-90FE-3C66FCA70E7CQ36097352-040AC771-DA2D-4BDD-8BA0-1C5BFD742687Q36105782-C7B11070-534A-4165-A77E-6D1AAA1EB15CQ36171833-A94E6CFB-547F-4C1B-B07A-A4BE46B018DAQ36239578-D7678767-1E1A-418F-A79D-0B83F45CA516Q36262823-1492C9D3-39D8-43A2-964D-814331A55E37Q36438523-89BC7551-67F7-412B-AF9C-55F8C85E9CA2Q37036833-2BE718CE-50FD-4E25-97E3-F1594281CE12Q37069837-0E0834EA-8C1E-43C9-AE95-6A55DECC4FF1Q37073506-B8E0FE2D-5F00-4CF3-8041-97CBA4B21573Q37254327-5E3BDBF4-B9F3-487D-9077-D7E99133460FQ37360774-AB09FA13-F003-4732-A423-B6450B5A9507Q37619134-092D7E64-B6AF-4694-B1F5-24AEBF6EAB1EQ38025633-AE1DC14C-A94D-4E03-8466-A67446FDF9E8Q38283531-90C360C0-44C4-4568-BB08-0E195BF10E9AQ38707583-D8B39AFF-96E8-4185-B56C-AC2B69D0811EQ38811735-898AB7D7-EFB5-4D2F-83D4-936F273583EAQ40476608-78377DA1-3979-48E5-AA7D-ABEF8BDECF52Q41933100-3AA072D5-FE09-4E31-AD17-98E48E8E82A5Q45324321-91CCA882-A2A2-4648-AF0D-95E7AD783F24Q47313525-90751779-258F-4A23-968C-76078A4BA6A6Q54987756-B93DB712-8B4A-4633-90CB-387C8F56C2BFQ55359818-389F0DB5-2916-454B-8F06-5DD0CE3455BAQ56974226-5C197909-50FF-43F9-8D0F-84CDDFF64CDDQ58451698-173E4505-0A24-458B-A4E0-06DE7E67A643
P2860
Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Longitudinal analysis of early ...... eactive neutralizing activity.
@ast
Longitudinal analysis of early ...... eactive neutralizing activity.
@en
type
label
Longitudinal analysis of early ...... eactive neutralizing activity.
@ast
Longitudinal analysis of early ...... eactive neutralizing activity.
@en
prefLabel
Longitudinal analysis of early ...... eactive neutralizing activity.
@ast
Longitudinal analysis of early ...... eactive neutralizing activity.
@en
P2093
P2860
P356
P1433
P1476
Longitudinal analysis of early ...... eactive neutralizing activity.
@en
P2093
Diana Edo-Matas
Hanneke Schuitemaker
Judith A Burger
Pham Phung
Terri Wrin
Tom L G M van den Kerkhof
Zelda Euler
P2860
P304
P356
10.1128/JVI.06091-11
P407
P577
2011-12-07T00:00:00Z